Brachytherapy

Brachytherapy Devices Market Analysis Highlights the Impact of COVID-19, 2020-2024 | High Prevalence of Cancer to Augment Growth | Technavio

Wednesday, July 1, 2020 - 2:45pm

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • View the full release here: https://www.businesswire.com/news/home/20200701005460/en/
    Technavio has announced its latest market research report titled Global Brachytherapy Devices Market 2020-2024 (Graphic: Business Wire)
    Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied.
  • Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis.
  • A high prevalence of cancer has been instrumental in driving the growth of the market.

Vivos Inc Achieves Important Radiogel™ Development Milestones

Wednesday, June 24, 2020 - 12:30pm

Richland WA, June 24, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos announced today significant progress in its efforts to advance RadioGel for human therapy.

Key Points: 
  • Richland WA, June 24, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos announced today significant progress in its efforts to advance RadioGel for human therapy.
  • We believe that approval of the IDE will significantly enhance the potential partnering and licensing opportunities for Radiogel.
  • Dr. Mike Korenko stated, completion of our QMS and the initiation of biocompatibility testing are important milestones for Radiogel and are critical steps in our continuing efforts to bring Radiogel to the human market.
  • Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (Isopet) and in humans (Radiogel).

Vivos Inc Expands its Intellectual Property Protection

Wednesday, June 10, 2020 - 12:00pm

Richland WA, June 10, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos announced that is has submitted an international application based on its patent submittal last June.

Key Points: 
  • Richland WA, June 10, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos announced that is has submitted an international application based on its patent submittal last June.
  • Vivos Inc. has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (Isopet) and in humans (Radiogel).
  • Following this demonstration phase, Vivos can generate revenues through the sale of Isopet to University animal hospitals and private veterinary clinics.
  • Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated.

Second Ten Year Data Report Demonstrates Efficacy of Isoray’s Cesium-131 Internal Radiation Therapy in the Treatment of Prostate Cancer

Tuesday, June 2, 2020 - 1:13pm

The authors concluded that the study demonstrates that, Prostate brachytherapy treated with Cesium-131 achieves excellent long-term biochemical control.

Key Points: 
  • The authors concluded that the study demonstrates that, Prostate brachytherapy treated with Cesium-131 achieves excellent long-term biochemical control.
  • Woods noted that emerging treatment strategies for localized prostate cancer require years of follow-up, given the long natural history of this cancer.
  • Cesium-131 has the shortest half-life and highest energy of brachytherapy seeds commonly used in the treatment of prostate cancer.
  • Unlike external beam radiation, Cesium-131 internal radiation therapy is able to deliver a precise dosage and placement of Cesium-131 seeds, leaving healthy tissues and organs undamaged.

Vivos Inc Resumes IsoPet Animal Cancer Therapy

Friday, May 29, 2020 - 12:00pm

Richland WA, May 29, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc Resumes IsoPet Animal Cancer Therapy

Key Points: 
  • Richland WA, May 29, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc Resumes IsoPet Animal Cancer Therapy
    After several months of virus-related stand-down IsoPet therapy has been scheduled for the week of June 20.
  • Vivos Inc. has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (Isopet) and in humans (Radiogel).
  • The Isopet Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers.
  • Following this demonstration phase, Vivos can generate revenues through the sale of Isopet to University animal hospitals and private veterinary clinics.

Analysis on Impact of COVID19-Brachytherapy Devices Market 2020-2024 | High Prevalence of Cancer to Boost Growth | Technavio

Monday, May 18, 2020 - 8:30am

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43465

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43465
    Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.
  • Our brachytherapy devices market report covers the following areas:
    This study identifies increase in M&A and strategic alliances among vendors as the prime reasons driving the brachytherapy devices market growth during the next few years.
  • Backed with competitive intelligence and benchmarking, our research reports on the brachytherapy devices market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

iCAD Presents Positive New Clinical Data for Xoft Brain IORT at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

Wednesday, May 13, 2020 - 10:00pm

(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced positive new clinical data supporting the Xoft Axxent Electronic Brachytherapy (eBx) System for the treatment of glioblastoma multiforme (GBM) will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, which will take place May 29-31, 2020.

Key Points: 
  • (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced positive new clinical data supporting the Xoft Axxent Electronic Brachytherapy (eBx) System for the treatment of glioblastoma multiforme (GBM) will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, which will take place May 29-31, 2020.
  • As of December 2019, 8 patients from the IORT group were still alive, whereas none of the patients in the EBRT group survived.
  • Researchers concluded that IORT of recurrent GBM is feasible and provides encouraging local progression-free and overall survival, with a manageable toxicity profile.
  • After researching this modality for nearly four years, we are greatly encouraged by these clinical results and the benefits this treatment offers to patients.

Isoray Announces Record Third Quarter Fiscal 2020 Financial Results

Tuesday, May 12, 2020 - 9:17pm

RICHLAND, Wash., May 12, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the third quarter fiscal 2020 ended March 31, 2020.

Key Points: 
  • RICHLAND, Wash., May 12, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the third quarter fiscal 2020 ended March 31, 2020.
  • Revenue for the third quarter of fiscal 2020 grew 50% to a record $2.88 million versus $1.92 million in the prior year comparable period.
  • Prostate brachytherapy represented 84% of total revenue for the third quarter of fiscal 2020 compared to 88% in the prior year comparable period.
  • Shareholders equity at the end of the third quarter of fiscal 2020 totaled $5.82 million.

Centers for Medicare and Medicaid Services Approves Isoray’s Application for Billing Codes for the Intraoperative Use of Cesium-131

Tuesday, May 12, 2020 - 9:08pm

Isoray CEO Lori Woods said this is a key development in the use of Isorays proprietary isotope.

Key Points: 
  • Isoray CEO Lori Woods said this is a key development in the use of Isorays proprietary isotope.
  • We view the creation of these new codes as a very positive step forward in promoting patient access to treatment with Cesium-131 and ensuring that hospitals receive fair and adequate reimbursement for providing brachytherapy services with Cesium-131.
  • Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com .
  • Contact Media and Public Relations: Sharon Schultz (302) 539-3747 Investor Relations: Mark Levin (501) 255-1910

Global Brachytherapy Devices Market (2020 to 2024) - Featuring Becton, Carl Zeiss & CivaTech Oncology Among Others - ResearchAndMarkets.com

Tuesday, May 12, 2020 - 11:35am

The "Global Brachytherapy Devices Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Brachytherapy Devices Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • The brachytherapy devices market is poised to grow by $ 388.62 mn during 2020-2024 progressing at a CAGR of 8% during the forecast period.
  • The reports on brachytherapy devices market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The brachytherapy devices market analysis includes technology segment and geographic landscapes.